Tecan Group AG (BIT:1TECN)
Italy · Delayed Price · Currency is EUR | Market Cap | 3.28B +70.6% |
| Revenue (ttm) | 943.04M -4.0% |
| Net Income | -125.99M |
| EPS | -10.08 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 34.03 |
| Dividend | 3.26 (1.31%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | 297 |
| Open | 245.80 |
| Previous Close | 246.00 |
| Day's Range | 245.80 - 246.40 |
| 52-Week Range | 124.70 - 249.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has ... [Read more]
News
How to Invest in AI Drug Discovery
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operat...
Tecan Group AG at Morgan Stanley Global Healthcare Conference Transcript
Tecan Group AG at Morgan Stanley Global Healthcare Conference Transcript
Tecan Group AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted a strong leadership position in lab automation, ongoing digital transformation through AI partnerships, and robust growth in biopharma and Asia. The Rewired program aims for significant margin expansion by 2028, while supply chain and portfolio optimization remain key priorities.
Tecan price target raised to CHF 240 from CHF 220 at Berenberg
Berenberg raised the firm’s price target on Tecan (TCHBF) to CHF 240 from CHF 220 and keeps a Buy rating on the shares.
Tecan price target raised to CHF 178 from CHF 160 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tecan (TCHBF) to CHF 178 from CHF 160 and keeps an Equal Weight rating on the shares.
Tecan downgraded to Neutral from Outperform at Oddo BHF
Oddo BHF analyst Stephan Wulf downgraded Tecan (TCHBF) to Neutral from Outperform with a CHF 192 price target
Tecan price target raised to CHF 160 from CHF 142 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tecan (TCHBF) to CHF 160 from CHF 142 and keeps an Equal Weight rating on the shares.
Tecan Group AG Earnings Call Transcript: H1 2026
H1 2026 saw above-market growth in both segments, with sales up 3.4% in local currencies and solid profitability despite FX and transformation costs. The Rewired program is progressing, supporting operational improvements and long-term targets of CHF 1 billion sales and 20% EBITDA margin by 2028.
Tecan Group AG Quarterly report: H1 2026
Tecan Group AG has published its H1 2026 quarterly earnings report on August 11, 2026.
Tecan Group AG Slides: H1 2026
Tecan Group AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 11, 2026.
Tecan Group AG Earnings release: H1 2026
Tecan Group AG released its H1 2026 earnings on August 11, 2026, summarizing the period's financial results.
Tecan price target raised to CHF 176 from CHF 151 at Deutsche Bank
Deutsche Bank analyst Jan Koch raised the firm’s price target on Tecan (TCHBF) to CHF 176 from CHF 151 and keeps a Hold rating on the shares. Published first on…
Tecan price target raised to CHF 151 from CHF 138 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Tecan (TCHBF) to CHF 151 from CHF 138 and keeps a Hold rating on the shares.
Tecan upgraded to Buy from Neutral at UBS
UBS upgraded Tecan (TCHBF) to Buy from Neutral with a price target of CHF 208, up from CHF 162. The company’s potential to improve margins is not priced into the…
Tecan price target raised to CHF 142 from CHF 136 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Tecan (TCHBF) to CHF 142 from CHF 136 and keeps an Equal Weight rating on the shares. Published first…
Tecan Group AG Earnings release: Q1 2026
Tecan Group AG released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Tecan price target lowered to CHF 138 from CHF 148 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Tecan (TCHBF) to CHF 138 from CHF 148 and keeps a Hold rating on the shares.
Tecan price target lowered to CHF 136 from CHF 137 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Tecan (TCHBF) to CHF 136 from CHF 137 and keeps an Equal Weight rating on the shares.
Tecan price target lowered to CHF 148 from CHF 165 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Tecan (TCHBF) to CHF 148 from CHF 165 and keeps a Hold rating on the shares.
Tecan Group AG Earnings Call Transcript: H2 2025
2025 saw a slight sales decline and a net loss due to impairment, but strong cash flow and a robust order book support a stable dividend. The Rewire program targets CHF 1 billion sales and 20% EBITDA by 2028, with gradual market recovery and operational improvements expected.
Tecan Group AG Earnings release: H2 2025
Tecan Group AG released its H2 2025 earnings on March 16, 2026, summarizing the period's financial results.
Tecan Group AG Annual report: H2 2025
Tecan Group AG has published its H2 2025 annual report on March 16, 2026.
Tecan Group AG Slides: H2 2025
Tecan Group AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 16, 2026.
Tecan price target lowered to CHF 137 from CHF 142 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Tecan (TCHBF) to CHF 137 from CHF 142 and keeps an Equal Weight rating on the shares.
Tecan upgraded to Market Perform from Underperform at Bernstein
Bernstein upgraded Tecan (TCHBF) to Market Perform from Underperform with a CHF 156 price target The firm says the company is now better positioned for a recovery in life sciences…